NEW YORK (GenomeWeb) – CombiMatrix today announced that clinical reference lab ReproSource is now offering the company's chromosomal microarray analysis for miscarriage, or products of conception (POC) testing.
CombiMatrix has announced a number of similar partnerships over the last two years, including deals with American Pathology Partners, ProPath, and Manhattan Laboratories.
The company has said previously that POC analysis, which is intended to help physicians better determine if there is a genetic cause for a miscarriage or other related event, makes up a significant portion, though not a majority of its testing.
The firm saw an uptick in POC test volumes after guidelines released in 2013 by the American Congress of Obstetricians and Gynecologists and the Society of Maternal Fetal-Medicine recommending prenatal chromosomal microarray analysis as the preferred methodology to identify the cause of death in stillbirths.
"As we expand our focus to the care of fertility patients, we are pleased to offer our … service to ReproSource and their client base while concurrently benefitting from ReproSource's expertise and customer reach with reproductive endocrinologists," Combimatrix CEO Mark McDonough said in a statement.